tradingkey.logo
tradingkey.logo
Search

Biohaven's Phase 2 Obesity Study With Taldefgrobep Alfa, A Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

ReutersMar 19, 2026 11:57 AM

- Biohaven Ltd BHVN.N:

  • BIOHAVEN'S PHASE 2 OBESITY STUDY WITH TALDEFGROBEP ALFA, A NOVEL MYOSTATIN-ACTIVIN PATHWAY INHIBITOR, COMPLETES ENROLLMENT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI